Publications des scientifiques de l'IRD

Dumont Alexandre, Bodin C., Hounkpatin B., Popowski T., Traoré M., Perrin R., Rozenberg P. (2017). Uterine balloon tamponade as an adjunct to misoprostol for the treatment of uncontrolled postpartum haemorrhage : a randomised controlled trial in Benin and Mali. BMJ Open, 7 (9), e016590 [9 p.]. ISSN 2044-6055.

Titre du document
Uterine balloon tamponade as an adjunct to misoprostol for the treatment of uncontrolled postpartum haemorrhage : a randomised controlled trial in Benin and Mali
Année de publication
2017
Type de document
Article référencé dans le Web of Science WOS:000412650700142
Auteurs
Dumont Alexandre, Bodin C., Hounkpatin B., Popowski T., Traoré M., Perrin R., Rozenberg P.
Source
BMJ Open, 2017, 7 (9), e016590 [9 p.] ISSN 2044-6055
Objective: To assess the effectiveness of low-cost uterine tamponade as an adjunct to misoprostol for the treatment of uncontrolled postpartum haemorrhage (PPH) in low-resource settings. Design Randomised controlled trial. Setting: Seven healthcare facilities in Cotonou, Benin and Bamako, Mali. Population: Women delivering vaginally who had clinically diagnosed PPH that was suspected to be due to uterine atony, who were unresponsive to oxytocin and who needed additional uterotonics. Methods: Women were randomly assigned to receive uterine balloon tamponade with a condom-catheter device or no tamponade; both groups were also given intrarectal or sublingual misoprostol. Main outcome measure Proportion of women with invasive surgery or who died before hospital discharge. Results: The proportion of primary composite outcome did not differ significantly between the tamponade arm (16%; 9/57) and the standard second line treatment arm (7%; 4/59): relative risk 2.33 (95% CI 0.76 to 7.14, p= 0.238). A significantly increased proportion of women with tamponade and misoprostol versus misoprostol alone had total blood loss more than 1000 mL: relative risk 1.52 (95% CI 1.15 to 2.00, p= 0.01). Case fatality rate was higher in the tamponade group (10%; 6/57) than in the control group (2%; 1/59) (p= 0.059).
Plan de classement
Médecine [050MEDECI]
Localisation
Fonds IRD
Identifiant IRD
fdi:010076290
Contact